Jazz Pharmaceuticals Plc - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Jazz Pharmaceuticals, Inc. on January 5, 2012. The report discloses the holding of an investor conference call on the same date, which included financial information relating to the fiscal year ended December 31, 2011.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document serves as a notification that such information was presented during a conference call and is contained within an attached transcript (Exhibit 99.1), which is not included in the provided source text.
Material Changes
The filing does not detail specific material changes versus prior periods. It references the existence of financial information for the year ended December 31, 2011, but does not quantify year-over-year performance in the body of this report.
Guidance, Outlook, and Risks
The report includes a standard legal disclaimer stating that the information in Item 2.02 and the accompanying Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, and shall not be incorporated by reference into any other SEC filings.
Investor Verification Checklist
- Verify the specific financial results for the year ended December 31, 2011, by reviewing the transcript of the conference call (Exhibit 99.1) referenced in this filing.
- Confirm that the financial data presented in the conference call is not considered "filed" information under Section 18 of the Exchange Act.
- Check subsequent filings (e.g., Form 10-K) for the official, audited financial statements for the 2011 fiscal year.